[Download PDF] X-Chem and Vertex Enter into Multi-Target Genetic Disease Collaboration – Agreement will enable discovery of small-molecule leads against validated targets for severe, genetic diseases – X-Chem to receive upfront payment and potential research, development and regulatory milestones and licensing fees, plus additional royalties on future sales WALTHAM, Mass. – May 15, 2017 – […]
WALTHAM, Mass. –April 26, 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative DNA-encoded library platform (DEXTM) to the discovery of the next generation of small molecule therapeutics, announced today a publication in Nature. The article, co-authored by scientists from AstraZeneca Inc. and Heptares, Inc., describes the crystal structure of protease-activated […]
April 26, 2017|Nature|Structural insight into allosteric modulation of protease-activated receptor 2 Protease-activated receptors (PARs) are a family of G-protein-coupled receptors (GPCRs) that are irreversibly activated by proteolytic cleavage of the N terminus, which unmasks a tethered peptide ligand that binds and activates the transmembrane receptor domain, eliciting a cellular cascade in response to inflammatory signals […]
WALTHAM, Mass. – March 21, 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, today announced a partnership with Ono Pharmaceutical Co., Ltd. (Ono). Under the terms of the agreement X-Chem will apply its proprietary DEXTM libraries, which contain over […]
WALTHAM, Mass. – March 20 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, announced the signing of a broad drug discovery collaboration with Astellas Pharma Inc. (Astellas). The collaboration will enable the discovery of novel lead compounds for complex […]
WALTHAM, Mass. – February 15, 2017 – X-Chem, Inc. (X-Chem) announced today that it has expanded its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new drug leads for the treatment of inflammatory disease. The multi-target expansion builds on the parties’ existing discovery and license partnership, […]
2017 Jan. 5|Chembiochem.|Discovery of a potent BTK inhibitor with a novel binding mode using parallel selections with a DNA-encoded chemical library. We have identified and characterized novel potent inhibitors of Bruton’s tyrosine kinase (BTK) from a single DNA encoded library of over 110 million compounds using multiple parallel selection conditions…Analysis of the co-crystal structure of […]
WALTHAM, Mass. – December 20, 2016 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced that it entered into a multi-target drug discovery collaboration with Taiho Pharmaceutical Co. Ltd. This collaboration will grant Taiho access to X-Chem’s DEX™ […]
Dec 9, 2016|Nat Rev Drug Discov.|DNA-encoded chemistry: enabling the deeper sampling of chemical space. DNA-encoded chemical library technologies are increasingly being adopted in drug discovery for hit and lead generation…This Review provides an overview of the development and applications of DNA-encoded chemistry, highlighting the challenges and future directions for the use of this technology. [Read […]
Nov. 18, 2016|Proc Natl Acad Sci U S A.|Discovery of cofactor-specific, bactericidal Mycobacterium tuberculosis InhA inhibitors using DNA-encoded library technology. Millions of individuals are infected with and die from tuberculosis (TB) each year, and multidrug-resistant (MDR) strains of TB are increasingly prevalent…We describe here the use of DNA-encoded X-Chem (DEX) screening, combined with selection of […]
